Reata is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation. Reata’s two most advanced clinical candidates (bardoxolone methyl and omaveloxolone) target the important transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation.

 

 

Webcasts

05-11-2020

Reata Pharmaceuticals First Quarter Financial Results and Update on Development Programs

Webcast: click here

Press (05-11-2020): 
Reata Pharmaceuticals, Inc. Announces First Quarter 2020 Financial Results and Provides an Update on Development Programs

Press (05-04-2020): 
Reata Pharmaceuticals, Inc. to Report First Quarter 2020 Financial Results and to Provide an Update on Development Programs on May 11, 2020

Teleconference Information

Date: Monday, May 11, 2020
Time: 04:30 pm ET
Audience Dial-in (toll-free): (844) 348-3946
Audience Dial-in (international): (213) 358-0892
Access Code: 6936548

Read more
 MP3
 PDF

02-19-2020

Reata Pharmaceuticals Fourth Quarter and Full Year 2019 Financial Results and Update on Development Programs

Webcast: click here

Press (02-19-20): 
Reata Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2019 Financials and Provides an Update on Development Programs

Press (02-12-20): 
Reata Pharmaceuticals, Inc. to Report Fourth Quarter and Full Year 2019 Financials and to Provide an Update on Development Programs on February 19, 2020

Teleconference Information

Date: Wednesday, February 19, 2020
Time: 04:30 pm ET
Audience Dial-in (toll-free): 844-348-3946
Audience Dial-in (international): 213-358-0892
Access Code: 1434037

Read more
 MP3
 PDF

11-12-2019

Management Call to Discuss Positive Topline Pivotal Year 1 CARDINAL Data

Webcast: click here

Press (11-11-19): 
Reata Announces Positive Topline Year One Results From Pivotal Phase 3 Cardinal Study of Bardoxolone Methyl in Patients With Alport Syndrome

Press (11-12-19): 
Reata Pharmaceuticals, Inc. Announces Third Quarter 2019 Financial Results and an Update on Development Programs

Teleconference Information

Date: Tuesday, November 12, 2019
Time: 08:00 am ET
Audience Dial-in (toll-free): (844) 348-3946
Audience Dial-in (international): (213) 358-0892
Access Code: 4159656

Read more
 MP3
 PDF

Events and Presentations

06-01-2020

Corporate Presentation

 PDF

11-10-2019

2019 ASN Posters

Poster: C. Wanner, M.D., University Hospital Würzburg, Würzburg, Germany presented Effect of Bardoxolone Methyl on Kidney Events in Patients with Chronic Kidney Disease Stage 4 and Type 2 Diabetes at High Risk of Adverse Kidney Outcomes

Poster: P.E. Pergola M.D., Ph.D. Renal Associates, San Antonio, TX, USA presented A Cardiovascular Risk Mitigation Strategy on the Safety of Bardoxolone Methyl Post-BEACON

Read more
 PDF
 PDF

10-18-2019

CNBC Interviews Reata CEO Warren Huff

Video Thumbnail
Reata CEO on positive trial results for drug to treat Friedreich's ataxia

06-14-2019

2019 ERA-EDTA Posters & Presentation

Poster: B. Knebelmann, M.D., Ph.D., Professor of Nephrology, Hôpital Necker, Paris, France presented Baseline Characteristics of the “CARDINAL” Trial: A Phase 3 Study of the Efficacy and Safety of Bardoxolone Methyl in Patients with Alport Syndrome

Poster: P. Pergola, M.D., Ph.D., Renal Associates, San Antonio, TX, presented Safety and Efficacy of Bardoxolone Methyl in Patients with Rare Chronic Kidney Diseases

Poster: P. Pergola, M.D., Ph.D., Renal Associates, San Antonio, TX, presented Safety and Efficacy of Bardoxolone Methyl in Patients with Focal Segmental Glomerulosclerosis

Presentation: C. Wigley, VP of Research, Reata Pharmaceuticals, presented The Nrf2 Activator Bardoxolone Methyl Inhibits Cyst Formation, Reduces Inflammation, and Improves Mitochondrial Function in Cellular Models of Polycystic Kidney Disease

Read more
 PDF
 PDF

Vineet Jindal

Vineet Jindal

Vice President, Corporate
Communications & Strategy

 (855) 55-REATA